# Adrestia Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/adrestia-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.adrestia.squarespace.com
- Total disclosed funding: $9.2M
- Latest round: Series A (Dec 11, 2020)
- Investors on record: 2

## About

Based in Cambridge, UK, and founded in 2017, Adrestia Therapeutics Ltd, a spin-out of the University of Cambridge in the UK, operates as a drug development company that develops treatments for genetic diseases. The company was co-founded by its CSO, Steve Jackson, Gabi Balmus, and Yaron Galanty. In June 2023, Insmed, Inc. acquired Adrestia Therapeutics Ltd. As of 2024, the company is led by its CEO, Robert Johnson.

Adrestia Therapeutics offers a synthetic rescue drug development platform, which is a drug development platform that develops synthetic rescue therapies for genetic diseases. The firm’s synthetic rescue platform uses high-throughput techniques like whole genome assays to analyze vast amounts of genetic data. Through this analysis, the platform identifies genes functionally linked to the disease-causing mutation.

## Funding rounds

- Series A, Dec 11, 2020, $9.2M — GlaxoSmithKline, Ahren Innovation Capital

## Investors

- GlaxoSmithKline — Series A
- Ahren Innovation Capital (https://capitalatlas.ai/funds/ahren-innovation-capital) — Series A